We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $1.92B
1-Year Est. Return 85.52%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$1.18B
AUM Growth
-$112M
Cap. Flow
-$159M
Cap. Flow %
-13.49%
Top 10 Hldgs %
34.43%
Holding
372
New
125
Increased
6
Reduced
44
Closed
64

Top Buys

Rank Stock Value
1
MBC icon
MasterBrand
MBC
+$33.6M
2
NE icon
Noble Corp
NE
+$30.1M
3
COF icon
Capital One
COF
+$17.7M
4
LEN.B icon
Lennar Class B
LEN.B
+$15.2M
5
APLS
Apellis Pharmaceuticals
APLS
+$9.28M

Top Sells

Rank Stock Value
1
LEN icon
Lennar Class A
LEN
+$41.7M
2
OPEN icon
Opendoor
OPEN
+$27M
3
ENVA icon
Enova International
ENVA
+$22.8M
4
PPLI
People Inc
PPLI
+$20.2M
5
CND
Concord Acquisition Corp.
CND
+$15.6M

Sector Composition

Rank Sector Weight
1 Financials 33.32%
2 Healthcare 19.05%
3 Consumer Discretionary 8.98%
4 Energy 6.58%
5 Materials 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
126
Instil Bio
TIL
$49.2M
$343K 0.03%
+27,257
New +$1.35M
TERN
127
DELISTED
Terns Pharmaceuticals
TERN
$285K 0.02%
+28,000
New +$186K
ALT icon
128
Altimmune
ALT
$589M
$283K 0.02%
+17,178
New +$193K
ETNB
129
DELISTED
89bio
ETNB
$282K 0.02%
+22,178
New +$200K
NINE
130
DELISTED
Nine Energy Service
NINE
$279K 0.02%
+19,230
New +$151K
TUSK icon
131
Mammoth Energy Services
TUSK
$137M
$277K 0.02%
+32,070
New +$183K
VKTX icon
132
Viking Therapeutics
VKTX
$3.91B
$273K 0.02%
+29,000
New +$129K
PDSB icon
133
PDS Biotechnology
PDSB
$40.6M
$254K 0.02%
+19,280
New +$136K
CABA icon
134
Cabaletta Bio
CABA
$442M
$249K 0.02%
+26,963
New +$98.2K
ORMP icon
135
Oramed Pharmaceuticals
ORMP
$180M
$247K 0.02%
+20,537
New +$160K
PMTS icon
136
CPI Card Group
PMTS
$261M
$245K 0.02%
+6,787
New +$165K
CVRX icon
137
CVRx
CVRX
$146M
$239K 0.02%
+13,022
New +$161K
LUNA
138
DELISTED
Luna Innovations Incorporated
LUNA
$236K 0.02%
+26,853
New +$170K
SMTI icon
139
Sanara MedTech
SMTI
$313M
$226K 0.02%
+4,966
New +$171K
GIACW
140
DELISTED
Gesher I Acquisition Corp. Warrants
GIACW
$225K 0.02%
450,000
– –
CNCE
141
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$222K 0.02%
+38,058
New +$200K
SPRY icon
142
ARS Pharmaceuticals
SPRY
$532M
$222K 0.02%
+26,054
New +$169K
HROW icon
143
Harrow
HROW
$1.47B
$220K 0.02%
+14,905
New +$178K
BMEA icon
144
Biomea Fusion
BMEA
$91.1M
$219K 0.02%
+26,016
New +$222K
ATXS
145
DELISTED
Astria Therapeutics
ATXS
$219K 0.02%
+14,718
New +$152K
SMMT icon
146
Summit Therapeutics
SMMT
$10.8B
$216K 0.02%
+50,838
New +$92.5K
GRTS
147
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$213K 0.02%
+61,761
New +$176K
SRRK icon
148
Scholar Rock
SRRK
$5.74B
$210K 0.02%
+23,152
New +$186K
KLXE icon
149
KLX Energy Services
KLXE
$42.1M
$209K 0.02%
+12,102
New +$170K
BWMN icon
150
Bowman Consulting
BWMN
$472M
$207K 0.02%
+9,471
New +$165K
4 5
6
7 8

Similar funds

QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
RIL
Rothschild Investment LLC Chicago, Illinois $1.91B AUM 24.37% 1-Year Est. Return
MC
Maren Capital Chicago, Illinois $1.91B AUM 17.37% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $1.92B AUM 16.97% 1-Year Est. Return
BOH
Bank of Hawaii Honolulu, Hawaii $1.91B AUM 22.08% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return

683 Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, 683 Capital Management held 372 positions worth $1.18B, down 8.7% from $1.29B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

683 Capital Management withdrew a net $159M in Q4 2022, closing 64 positions and reducing 44 holdings. Its most notable exit was Lennar Class A, an estimated $41.7M position sold in full.

By sector, the portfolio is most concentrated in Financials at 33% of assets, down from 34% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, 683 Capital Management opened a new position in MasterBrand worth $31M.

  • 683 Capital Management's largest Q4 2022 buy was MasterBrand: 4,100,000 shares worth $31M.
  • 683 Capital Management added most to Capital One in Q4 2022, an estimated $17.7M increase.
  • 683 Capital Management's biggest Q4 2022 reduction was Enova International, cutting an estimated $22.8M.
  • 683 Capital Management fully exited Lennar Class A in Q4 2022, selling an estimated $41.7M.
  • 683 Capital Management's ten largest holdings make up 34% of its $1.18B portfolio in Q4 2022.
  • 683 Capital Management opened 125 new positions and closed 64 in Q4 2022.
  • 683 Capital Management's portfolio value fell 8.7% quarter-over-quarter to $1.18B.

Based on 683 Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.